MODERN METHODS OF DIAGNOSIS AND TREATMENT OF DIABETES MELLITUS USING EVIDENCE-BASED MEDICINE
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstrak:
Diabetes mellitus is one of the most common chronic noncommunicable diseases and represents a serious medical and social problem due to its high prevalence, risk of complications, and significant impact on patients' quality of life. With the rapid development of clinical diabetology, the application of evidence-based medicine principles in the diagnosis and treatment of this disease is particularly important. This article examines modern methods of diagnosing and treating diabetes mellitus using evidence-based medicine. It analyzes the capabilities of laboratory and instrumental diagnostic methods based on clinical guidelines, as well as evidence-based approaches to pharmacotherapy and non-drug treatment. It is shown that the implementation of evidence-based methods facilitates early detection of the disease, optimizes treatment strategies, and reduces the risk of acute and chronic complications of diabetes.
##plugins.themes.bootstrap3.article.details##
##submission.howToCite##:
##submission.citations##:
World Health Organization. (2023). Diabetes. World Health Organization.
International Diabetes Federation. (2021). IDF Diabetes Atlas (10th ed.). International Diabetes Federation.
American Diabetes Association. (2023). Standards of care in diabetes—2023. Diabetes Care, 46(Suppl. 1), S1–S291. https://doi.org/10.2337/dc23-SINT
European Association for the Study of Diabetes. (2022). EASD clinical practice recommendations for the management of diabetes. Diabetologia, 65(12), 1925–1966. https://doi.org/10.1007/s00125-022-05787-2
Nathan, D. M., Genuth, S., Lachin, J., Cleary, P., Crofford, O., Davis, M., Rand, L., & Siebert, C. (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The New England Journal of Medicine, 329(14), 977–986. https://doi.org/10.1056/NEJM199309303291401
UK Prospective Diabetes Study (UKPDS) Group. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. The Lancet, 352(9131), 837–853. https://doi.org/10.1016/S0140-6736(98)07019-6
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., & Broedl, U. C. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. The New England Journal of Medicine, 373(22), 2117–2128. https://doi.org/10.1056/NEJMoa1504720
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018). Management of hyperglycemia in type 2 diabetes, 2018. Diabetes Care, 41(12), 2669–2701. https://doi.org/10.2337/dci18-0033
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. (2008). 10-year follow-up of intensive glucose control in type 2 diabetes. The New England Journal of Medicine, 359(15), 1577–1589. https://doi.org/10.1056/NEJMoa0806470